Central Nervous System Neuroblastoma, FOXR2-Activated — Variants & evidence

Central Nervous System Neuroblastoma, FOXR2-Activated — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FOXR2 Rearrangement3
(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID11527 In the 2016 study by Sturm et al., the authors performed comprehensive molecular profiling, including DNA methylation arrays, transcriptomics, and genome-wide sequencing, on 323 institutionally diagno… (full text at CIViC) PMID 26919435 · Sturm et al., 2016 · Open in CIViC	civic
〃	Diagnostic	B	Supports Positive	4	accepted	EID11528 DNA methylation profiling of 84 tumors initially diagnosed as CNS-PNET identified CNS neuroblastoma with FOXR2 activation (CNS NB-FOXR2) as a distinct molecular subgroup, presented in 24% (20/84) of c… (full text at CIViC) PMID 33536079 · Korshunov et al., 2021 · Open in CIViC	civic
〃	Diagnostic	B	Supports Positive	4	accepted	EID12521 In this Swedish population-based study, the authors retrospectively re-evaluated 71 poorly differentiated supratentorial CNS tumors in children, previously diagnosed as CNS-PNETs, to assess their mole… (full text at CIViC) PMID 36895035 · Schepke et al., 2023 · Open in CIViC	civic

Data updated 9 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.